Fedha

Beta
Hisa unazofuatilia
Sekta za hisa
Alama
Alama
Bei
Tofauti
Tofauti ya asilimia
Mwenendo wa data
Bei ya Awali
Fungua
Juu
Chini
Kiasi cha mauzo ya hisa
Mtaji wa Soko
SIXB
Materials
SIXB
Materials
SIXB
-1.41%
1,076.13
-15.38
-1.41%
—1,091.511,090.401,090.401,073.69——
SIXC
Communications
SIXC
Communications
SIXC
-0.55%
606.74
-3.37
-0.55%
—610.11610.11610.29606.17——
SIXE
Energy
SIXE
Energy
SIXE
+0.88%
1,248.82
+10.84
+0.88%
—1,237.981,237.831,252.411,225.03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.17%
1,724.36
-20.35
-1.17%
—1,744.711,740.951,747.291,721.57——
SIXM
Financials
SIXM
Financials
SIXM
-0.72%
635.59
-4.59
-0.72%
—640.18639.92643.19634.73——
SIXR
Staples
SIXR
Staples
SIXR
-0.76%
843.15
-6.43
-0.76%
—849.58845.27851.68839.47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.55%
216.29
-1.19
-0.55%
—217.48217.48218.16215.51——
SIXT
Technology
SIXT
Technology
SIXT
+0.08%
3,263.41
+2.72
+0.08%
—3,260.693,273.363,287.813,240.78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.34%
939.24
-3.21
-0.34%
—942.45939.39948.80933.98——
SIXV
Health care
SIXV
Health care
SIXV
-0.29%
1,462.56
-4.24
-0.29%
—1,466.801,464.701,467.191,458.36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.71%
2,380.40
-17.10
-0.71%
—2,397.502,395.032,412.012,370.64——
Mapato ya Q1 2026 • kesho saa 5:00 PM
Angalia maelezo
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ 24.81
+0.16%
(+0.040) Siku 1
US$ 24.81
0.00% (0.00)
Baada ya saa
Imefungwa: 4 Mei, 16:00:00 GMT -4  ·   USD
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya RARE...
Fungua
US$ 24.69
Juu
US$ 25.32
Chini
US$ 24.49
Mtaji wa soko
2.44B
Wastani wa kiasi cha mauzo
1.96M
Kiasi cha mauzo ya hisa
1.85M
Juu kwa wiki 52
US$ 42.37
Chini kwa wiki 52
US$ 18.29
EPS
-US$ 5.83
Beta
0.39
Hisa za wawekezaji
98.32M
Idadi ya wafanyakazi
elfu 1
Habari
Kutoka kwenye vyanzo vya wavuti
Wasifu
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Kuhusu Ultragenyx Pharmaceutical Inc
Afisa Mkuu Mtendaji (CEO)Emil Kakkis
Wafanyakazielfu 1.37
Lilianzishwa2010
Makao makuuNovato, California, Marekani
Sekta-
Tovutiultragenyx.com
Simu inayofuata baada ya saa 18:00:16
Kesho, saa 17:00
Kipindi cha Kifedha
Robo1 2026
Mapato Yaliyosawazishwa kwa Kila Hisa au Kadirio
-/ (-1.46 inakadiriwa)USD
Mapato au Kadirio
-/ (158.41M inakadiriwa)USD
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 1 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari: mapato yajayo
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika USD
Loading Previous Earnings...
Taarifa ya mapato
Mapato
Mapato halisi
Thamani zote katika USD
Mac 2025
Jun 2025
Sep 2025
Des 2025
Mapato
139.29M
166.50M
159.93M
207.28M
Gharama ya bidhaa zilizouzwa
194.43M
187.74M
244.20M
232.62M
Gharama ya mapato
194.43M
187.74M
244.20M
232.62M
Gharama za utafiti na maendeleo
-
-
-
-
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
87.80M
86.65M
86.62M
87.94M
Gharama ya uendeshaji
87.80M
86.65M
86.62M
87.94M
Jumla ya gharama za uendeshaji
282.23M
274.38M
330.82M
320.56M
Mapato ya uendeshaji
-142.94M
-107.89M
-170.89M
-113.28M
Mapato mengine yasiyo ya uendeshaji
elfu 837.00
2.14M
-1.04M
elfu -934.00
EBT ikijumuisha vipengee visivyo vya kawaida
-149.77M
-114.00M
-179.54M
-127.69M
EBT bila kujumuisha vipengee visivyo vya kawaida
-149.61M
-114.00M
-180.22M
-127.17M
Gharama ya kodi ya mapato
1.31M
elfu 947.00
elfu 873.00
elfu 870.00
Kiwango cha kodi kinachotumika
-0.87%
-0.83%
-0.49%
-0.68%
Gharama nyingine za uendeshaji
-
-
-
-
Mapato halisi
-151.08M
-114.95M
-180.41M
-128.56M
Kiwango cha faida halisi
-108.46%
-69.04%
-112.81%
-62.02%
Mapato kwa kila hisa
-1.57
-1.17
-1.81
-1.29
Mapato ya riba na uwekezaji
6.83M
5.79M
5.86M
6.51M
Gharama ya riba
-14.34M
-14.04M
-14.15M
-19.47M
Jumla ya gharama halisi za riba
-7.51M
-8.25M
-8.28M
-12.96M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
-133.95M
-99.27M
-162.28M
-104.50M
Faida au hasara kutokana na uuzaji wa vipengee
-
-
-
-
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
UsaidiziTuma maoniFaraghaSheria na MashartiKanusho

Utafiti

Majukumu yangu
Bado hujaanzisha jukumu lolote
Majukumu yako yataonekana hapa. Ratibu majukumu na uruhusu Google Finance ifanye kazi ukiwa mbali.
Violezo
Muhtasari wa hisa unazofuatilia
Uchanganuzi wa kila siku wa kabla ya soko kufunguliwa wa orodha ya hisa unazofuatilia
Mapato Yajayo
Ripoti za mapato yajayo katika wiki
Mabadiliko ya Bei na Kiasi cha Hisa Kisicho cha Kawaida
Onyo la mapema kuhusu mabadiliko ya kiwango cha miamala leo
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
UsaidiziTuma maoniFaraghaSheria na MashartiKanusho